Skip to main content

Health service navigation app scores $1M and more briefs

Also, a new AI-driven genomics platform developed in Queensland can identify cancer biomarkers and predict tumour responses to chemotherapy.
By Adam Ang
Interface of the Indi app for navigating health services

Photo courtesy of Indi

AI health service navigation app bags $1M

Australian startup Indi has raised A$1.46 million ($950,000) in a funding round led by Giant Leap, with support from Antler and several angel investors. 

It offers an AI-powered application that provides a platform for connecting parents, therapists, and clinicians. It aims to help parents navigate healthcare, allied health, education, and National Disability Insurance Scheme (NDIS) services. 

Based on a media statement, Indi will use its fresh funds to grow its team, accelerate app development, and secure partnerships with allied health clinics. 


University of Queensland develops AI-powered cancer genomics platform

The University of Queensland, in collaboration with the University of Cambridge, has developed an AI-driven genomics platform to study how DNA is copied in cancer cells and disrupted during chemotherapy.

The system, called DNAscent, combines AI with nanopore DNA sequencing to more precisely measure DNA replication stress, which is a key hallmark of cancer, and identify biomarkers that could help predict tumour responses to chemotherapy.

Researchers said the platform, which builds on earlier methods, could ultimately support the development of personalised cancer treatments with fewer toxic side effects.


Harrison.ai rebrands Annalise.ai under one radiology brand

Harrison.ai has announced that its Annalise.ai imaging solutions will now operate under the name Harrison.ai Radiology.

The move unifies its radiology offerings under one global brand to simplify engagement for healthcare providers as it scales internationally.

Harrison.ai’s radiology AI tools have been adopted in more than 1,000 sites in over 40 countries, including public emergency departments in Hong Kong, 40 NHS Trusts in the United Kingdom, and major providers across Europe, the United States, and Australia. 

The company says the rebrand "will not affect existing solutions, agreements, or support."